The FDA critical path initiative and its influence on new drug development.
暂无分享,去创建一个
[1] Robert M Califf,et al. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. , 2007, Health affairs.
[2] J. Woodcock,et al. The Prospects for “Personalized Medicine” in Drug Development and Drug Therapy , 2007, Clinical pharmacology and therapeutics.
[3] C Thomas Caskey,et al. The drug development crisis: efficiency and safety. , 2007, Annual review of medicine.
[4] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[5] L. Lesko,et al. Paving the Critical Path: How can Clinical Pharmacology Help Achieve the Vision? , 2007, Clinical pharmacology and therapeutics.
[6] John P. Moore,et al. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. , 2008, Annual review of medicine.
[7] M. Krucoff,et al. Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative. , 2005, Journal of electrocardiology.
[8] A. Zaas,et al. The effect of toll-like receptors and toll-like receptor genetics in human disease. , 2008, Annual review of medicine.
[9] F. Frueh,et al. Application of Pharmacogenomics in Clinical Pharmacology , 2006, Toxicology mechanisms and methods.
[10] Innovation OR Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .
[11] Van V. Brantner,et al. Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.
[12] Alastair J J Wood,et al. A proposal for radical changes in the drug-approval process. , 2006, The New England journal of medicine.